Elder Pharmaceuticals is currently trading at Rs. 176.00, up by 0.80 points or 0.46% from its previous closing of Rs. 175.20 on the BSE.
The scrip opened at Rs. 174.80 and has touched a high and low of Rs. 177.90 and Rs. 174.80 respectively. So far 5932 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 349.00 on 13-Dec-2013 and a 52 week low of Rs. 162.00 on 14-Aug-2014.
Last one week high and low of the scrip stood at Rs. 187.40 and Rs. 173.30 respectively. The current market cap of the company is Rs. 361.45 crore.
The promoters holding in the company stood at 25.26% while Institutions and Non-Institutions held 29.77% and 44.97% respectively.
Elder Pharmaceuticals has forayed into fast-growing Indian mouthwash category in oral care segment, where the company is eyeing 5-7 per cent share in the next few years. In this regard, the company has launched AMPM range of mouthwash with an addition of a range for smokers/tobacco users.
Developed by R&D scientists at Elder Pharma in a joint co-operation with dentists, the AMPM mouthwash has a key ingredient, ‘triclosan’, an antibacterial and anti-fungal agent. Triclosan has been shown to be effective in reducing and controlling bacterial contamination and fighting germs.
Further, the company is planning to launch mouthwashes based on natural ingredients like aloe vera, green tea and probiotics under the AMPM range.
Elder Pharmaceuticals has around six manufacturing units in India, all as per international standards. Post increasing its stake in Elder Biomeda AD and Neutrahealth PLC, EPL also has access to the manufacturing units of these companies in Bulgaria and Birmingham, UK respectively coupled with distribution network and brands of the same.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: